Antabio
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
436 Rue Pierre Et Marie Curie, Labege, O...Phone Number
+33 531471857Website
www.antabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Antabio
Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. The company’s lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).Explore more
Antabio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Antabio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Antabio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Antabio had a recent Job posting/layoffs
Check out if Antabio is spiking on competitors!
Check if Antabio has recently received funding, and reach out quickly before it becomes old news!
Antabio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Antabio
Product Launch: Get notified when Antabio launches new products
Funding: Get notified immidiatlly once Antabio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Antabio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Antabio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Antabio.
Antabio financials insights
Gather financial insights about Antabio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Share Placement
$2.8M
Series A
$8.6M
2023
Series B
$26.9M
Antabio Tech Stack
A closer look at the technologies used by Antabio
See more technologies
Most Recent Scoops
Open Position
Open Position
Funding
Open Position
Open Position
Antabio News & Media
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections
MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumanniiFrench multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
LABÈGE, TOULOUSE, MARCY L'ETOILE and LYON, France, Jan. 6, 2022 /PRNewswire/ -- The ARPEGE[1] project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9...Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens
Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of antibacterial treatments against life threatening WHO critical priority pathogens, announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio's MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor ANT3310. QIDP was granted to MEM-ANT3310 for the treatment of complicated urinaBioSpace Global Roundup, Jan. 9
Pharma and biotech companies from across the globe provide business and pipeline updates.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Antabio
Sign Up For FreeTo access detailed company insights
Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmon... Read More
